Ken Griffin Abbott Laboratories Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$100.73 - $112.44 $111 Million - $124 Million	1,101,900 Added 72.36%	2,624,700 $273 Million
Q1 2024 May 15, 2024	SELL	$109.52 - $120.96 $18.9 Million - $20.9 Million	-172,900 Reduced 10.2%	1,522,800 $173 Million
Q4 2023 Feb 14, 2024	BUY	$90.19 - $110.4 $32.9 Million - $40.3 Million	364,800 Added 27.41%	1,695,700 $187 Million
Q3 2023 Nov 14, 2023	SELL	$95.53 - $114.62 $5.61 Million - $6.73 Million	-58,700 Reduced 4.22%	1,330,900 $129 Million
Q2 2023 Aug 14, 2023	SELL	$100.78 - $112.29 $9.36 Million - $10.4 Million	-92,900 Reduced 6.27%	1,389,600 $151 Million
Q1 2023 May 15, 2023	SELL	$96.86 - $114.01 $17.5 Million - $20.6 Million	-181,000 Reduced 10.88%	1,482,500 $150 Million
Q4 2022 Feb 14, 2023	BUY	$95.06 - $111.52 $46 Million - $53.9 Million	483,700 Added 41.0%	1,663,500 $183 Million
Q3 2022 Nov 14, 2022	SELL	$96.76 - $112.03 $13.1 Million - $15.2 Million	-135,500 Reduced 10.3%	1,179,800 $114 Million

3,135

1.33B

8.63M

7.17M

Ticker ABT
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 1,751,219,968
Market Cap $197B
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.